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Is mucinous carcinoma of the colorectum a distinct genetic entity?
C Hanski
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Summary Mucinous carcinomas are defined on the basis of the amount of the mucus component in the
tumour mass. Apart from this quantitative criterion, a number of clinicopathological parameters (such as
localisation, prevalence in different countries and age groups, association with HNPCC and inflammatory
processes) and genetic alterations (e.g. frequency of mutation in Ki-ras and p53 genes, level of MUC2
expression) differentiate these tumours from the non-mucinous ones. Since a different set of genetic lesions
implies different inducing agents, these observations suggest that there may be a 'mucinous pathway of
carcinogenesis'. Further identification of genetic changes characteristic of the mucinous phenotype will help to
understand the aetiology of these tumours and possibly establish markers for detection of the high-risk group.
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The designation mucinous carcinomas is applied to colorectal
tumours in which mucus secretion largely contributes to the
tumour growth. Different authors classified colonic tumours
as mucinous when the mucin lakes represented 50% (Pihl et
al., 1980) to 80% (Umpleby et al., 1985) of the tissue; the
definition set by World Health Organization and applied in
the more recent reports and in the present minireview
requires the mucinous component to represent more than
50% of the tumour (Jass and Sobin, 1990).
Whether the mucinous phenotype is associated with
relatively poor prognosis is a matter of controversy; more
recent multivariate analyses of the course of the disease in a
large number of patients indicate that the mucinous car-
cinomas of the colorectum do not differ in their clinical
behaviour from non-mucinous (Sasaki et al., 1987; Halvorsen
and Seim, 1988; Hermanek et al., 1989) or signet ring cell
carcinomas (Sasaki et al., 1987). The pattern of the genetic
lesions in mucinous carcinomas is, however, different from
that in non-mucinous ones. Some of these differences are
obviously related to the mucinous phenotype (like the level of
MUC2 expression) and may be epiphenomenal, while others
(such as activation of proto-oncogenes and inactivation of
suppressor genes) belong to the group of lesions assumed to
be fundamental in carcinogenesis. The present analysis of the
recently defined genetic differences as well as indicators of
inherent genetic differences between the mucinous and non-
mucinous phenotype suggests that distinct molecular lesions
occur during the development ofthese two types ofcolorectal
carcinoma.
Clinicopathological parameters
Similar prevalence in the left and the right colon
Several studies indicate that 19-40% of non-mucinous
sporadic carcinomas are located in the right colon while the
majority is found in the left colon (Symonds and Vickery,
1976; Umpleby et al., 1985; Milne, 1994). By contrast, the
prevalence ofmucinous carcinomas is approximately equal in
both segments (Symonds and Vickery, 1976; Sundblad and
Paz, 1982; Umpleby et al., 1985). For example, in a recent
study of 80 mucinous carcinomas 46% were localised in the
right (including ascending and transverse colon) and 54% in
the left colon segment (including descending, sigmoid colon
and rectum). Among patients with non-mucinous carcinomas
this distribution was 19% and 81% respectively (Hanski et
al., 1995). Thus in the right colon about every fifth, while in
the left colon every tenth, tumour exhibits a mucinous
phenotype.
This difference in preferential localisation suggests that the
development of mucinous tumours, in contrast to non-
mucinous ones, is less dependent on endogenous factors that
show a proximal-to-distal gradient.
Different prevalence in different countries
There are no separate data on the incidence of colorectal
mucinous carcinomas in different countries. They can, how-
ever, be estimated from the available prevalence of mucinous
carcinomas and the incidence of sporadic colon carcinomas.
Since the available data do not take into account potential
variations in the prevalence of inherited cancer syndromes,
they can be compared only if the assumption is made that
inherited cancers represented a minor fraction of the inves-
tigated tumours.
For example, the prevalence of mucinous carcinomas
among all sporadic colorectal carcinomas ranges from 6% in
Japan (Okuno et al., 1988; Yamamoto et al., 1993) to 15% in
the USA (Symonds and Vickery, 1976). Since large patient
groups have been evaluated according to similar criteria,
these variations are unlikely to be due to a sampling error.
While the incidence of sporadic colon carcinomas is less than
3-fold higher in the USA than in Japan, the resulting annual
incidence of mucinous cancers is about 7-fold higher in the
USA. Thus the incidence pattern of mucinous carcinomas
appears to show a different dependence from the life and
dietary conditions than that of non-mucinous adenocar-
cinomas of the colon.
Different prevalence in young andelderly age groups
The non-mucinous carcinoma is most frequent in 60-69-
year-old patients (Umpleby et al., 1985; Hanski et al., 1995)
while the mucinous carcinoma is most frequent at the age
70-79 years. In patients younger than 20 years colon car-
cinoma is extremely rare (incidence 1 in 10 million) but when
observed it is in 80-90% of the mucinous phenotype (Fer-
guson and Obi, 1971; Koh et al., 1980; Odone et al., 1982;
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Pratt et al., 1987; Angel et al., 1992). The age distribution
appears to vary widely between different communities:
patients under 35 years account for 34% of mucinous car-
cinomas in Jordanians but only for 3.5% in Nova Scotians
(Dajani et al., 1980). The occurrence of mucinous colorectal
carcinomas in children and very young patients suggests a
hereditary nature for at least some of these tumours.
Frequent occurrence ashereditary non-polyposis colon cancer
Hereditary non-polyposis colorectal cancer (HNPCC) is an
autosomal' dominantly inherited susceptibility to early-onset
colorectal cancer in the absence of diffuse polyposis (average
age 44 years), a predominance of cancer proximal to the
splenic flexure (approximately 70%) and an excess of syn-
chronous and metachronous colonic cancers (>40% at 10
years after initial colonic cancer) (Jass, 1993; Lynch et al.,
1993). HNPCC accounts for about 3-30% of all colorectal
cancers (Lynch and Lynch, 1994).
Mucinous phenotype appears to occur more frequently
among HNPCCs than among sporadic cancers. Mecklin et
al. (1986) found in 100 Finnish HNPCC patients 26% car-
cinomas with more than 60% mucin content and only 15%
in patients with sporadic tumors. Among the 77 American
patients with HNPCC investigated by Lynch et al. (1991)
20% were diagnosed as mucinous as compared with 8% in
the control group. Jass et al. (1994) observed 19% of
mucinous carcinomas among 140 HNPCCs vs 10% expected
among sporadic colon cancers. A high percentage of
mucinous carcinomas was observed in several small groups of HNPCC patients (Budd and Fink, 1981; Abusamra et al.,
1987; Purtilo et al., 1987; Calmes et al., 1992).
The recent findings on the genetic basis of HNPCC suggest that inherited mutations in hMSH2 and hMLHI genes
account for the majority of the HNPCC cases (Leach et al.,
1993; Parsons et al., 1993; Aaltonen and Peltomaki, 1994;
Loeb, 1994; Peltomaki, 1994; Smith, 1994). These genes encode the human homologues of bacterial proteins MutS
and MutL, which are part of the base mismatch repair
system. Loss of their function may explain the erroneous
replication of microsatellites in hereditary colon cancers
(Umar et al., 1994). Since the frequency ofreplication error-
positive (RER+) colon cancers is higher than that of
HNPCCs, the defective mismatch repair may contribute to
the development of both hereditary and sporadic colonic
tumours (Kim et al., 1994). The mutations at codons 12 or
13 in Ki-ras gene were found in 61% of HNPCC patients, a
percentage higher than found in the group of sporadic cases
(40%) (Aaltonen et al., 1993). These morphological and
genetic observations support the notion that a considerable
percentage of the HNPCCs exhibit mucinous phenotype characterised by a high frequency of Ki-ras mutations.
Association with Crohn's disease and ulcerative processes
Patients with Crohn's disease have several-fold increased risk
of colorectal carcinoma as compared with the general population. In two studies 50% (Hamilton, 1985) or 29%
(Choi and Zelig, 1994) of these carcinomas were identified as
mucinous or mucinous and signet ring cell carcinomas
respectively. Other groups did not report more frequent
occurrence of mucinous tumours in patients with Crohn's
disease (Lightdale et al., 1975; Gyde et al., 1980; Ekbom et
al., 1990). Conversely, the analysis of 120 mucinous car-
cinomas showed that only 15 tumours were associated with
colitis or ulcerative colitis (Symonds and Vickery, 1976). These data indicate that the inflammatory process is not
necessary but it may facilitate the preferential development of
the mucinous phenotype.
High incidence after ionising irradiation
Patients treated by radiotherapy of cancers localised in the
abdomen (usually a total local dose in the range of 60Gy fractionated over about 30 weeks), have an increased risk of
developing colonic cancers. Mucinous carcinomas represent
26-58% of these tumours (Castro et al., 1973; Kato et al.,
1981; Jao et al., 1987). The development of mucinous car-
cinomas was also observed in 47% of rats after local irradia-
tion of the colon with a single dose of 45 Gy (Denman et al.,
1978). Among the atomic bomb survivors who suffered a
total dose below 1 Gy, the risk of colon cancer was increased
but there was no frequency increase of mucinous phenotype
(Nakatsuka et al., 1992). Thus it is possible that radiation
enteritis rather than radiation mutagenesis is the factor
facilitating the development of the mucinous phenotype.
Genetic alterations
Lowfrequency ofp53 mutation and LOH
The nuclear phosphoprotein p53 appears to function as a
'guardian of the genome' (Lane, 1992; Levine, 1993), arrest-
ing cells in GI phase in response to DNA damage and in
some cases triggering cell death by apoptosis (Lane, 1993;
Lee et al., 1994). Further, recent data indicate that p53 may
directly and indirectly stimulate DNA repair (Smith et al.,
1994). Mutation of the p53 gene is one of the most frequent
genetic lesions associated with cancer (Greenblatt et al.,
1994). Mutations occur most commonly in four regions of
the p53 gene ('hotspots'), highly conserved among species.
The p53 gene mutation is frequently but not systematically
(with concordancy of about 70%; Cripps et al., 1994) related
to accumulation of p53 protein. While the physiological con-
centrations of the wild-type p53 protein are immunohisto-
chemically undetectable, the overexpression of the p53
molecule can usually be visualised. It is rare in adenomas but
occurs in 50-73% of sporadic colon cancers (Van den Berg
et al., 1989; Purdie et al., 1991; Scott et al., 1991; Hanski et
al., 1992), indicating that it is a late event of colon car-
cinogenesis. The overexpression of p53 was detected with the
monoclonal antibody PAb 1801 in 73% of non-mucinous
colorectal adenocarcinomas but only in 25% of the mucinous
carcinomas (Campo et al., 1991). Similar results have been
obtained with the polyclonal antibody CM-1 (72% and 36%
respectively) (Hanski et al., 1992), indicating that the
difference was not due to a lost epitope. The frequency of
mutations in non-selected colonic carcinomas detected by
PCR-based techniques is 50-63% (Greenblatt et al., 1994;
Hamelin et al., 1994a; Costa et al., 1995). By contrast, the
sequencing of relevant exons of p53 gene in the DNA
isolated and amplified from mucinous carcinomas of the
colon revealed mutations in only 25-31% of cases (Costa et
al., 1995; C Hanski et al., unpublished), thus indicating that
not only the overexpression but also the mutation of the p53
gene occurs less frequently in mucinous than in the non-
mucinous tumours. The predominant type of mutation was
GC-*AT transitions, the most frequent type of p53 muta-
tions in sporadic carcinomas. These results suggest that the
alterations of the p53 gene in mucinous colorectal car-
cinomas are qualitatively similar, although less frequent than
in non-mucinous cancer. These lesions seem therefore to be
not essential for the development of the majority of
mucinous colorectal tumours.
The inactivation of p53 function can occur not only
through somatic mutation of the p53 gene but also by com-
plex formation with viral oncogene products, cellular pro-
teins or by alteration in subcellular localisation (Chang et al.,
1993; Zambetti and Levine, 1993). The normal protein binds
to SV40 large T antigen, to the adenovirus protein E1B, the
papilloma virus protein E6, as well as to the cellular nrotein
MDM2 (Chang et al., 1993). Binding of p53 to SV40 large
antigen or E1B protein leads to an increased half-life of p53
while E6 proteins facilitate the degradation of p53 (Scheffner
et al., 1990; Werness et al., 1990). Tumours resulting from
this pathway may contain only wild-type p53 allele. Indeed,
in both cervical carcinomas associated with papilloma virus
and in sarcomas with MDM2 amplification, p53 mutations
appear to be rare, whereas they are common in anogenital
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Table I Incidence of mucinous colon carcinoma (Muc-CA) in different countries
Colon carcinoma Prevalence Muc-CA No. of colon
incidence of Muc-CA incidence per CA cases
per 105 persons (%) 106 persons evaluated Reference
29.2 6.4 19 Japan 540 Okuno et al. (1988)a
29.2 6.6 19 Japan 662 Yamamoto et al. (1993) (>50%)
53 9 48 Nova Scotia 417 Dajani et al. (1980) (>50%)
56.3 11 62 England 669 Umpleby et al. (1985) (>60%)
48.5 10 49 Norway 534 Halvorsen and Seim, (1988)a
60.7 14 85 Australia 519 Pihl et al. (1980) (>50%)
33 15 50 Finland 75 Mecklin et al. (1986) (>60%)
79.2 15 119 USA 893 Symonds and Vickery (1976) (>60%)
14.6 19 28 India 118 Suma and Nirmala (1992) (>50%)
13 22 29 Jordan 141 Dajani et al. (1980) (>50%)
Incidence of all cancers is an estimate derived from the IARC statistics on cancer incidence in different countries
(Waterhouse et al., 1982). The incidence of mucinous carcinomas is calculated from the prevalence data in individual
reports. The percentage of mucin in the sections used by each author to define the mucinous phenotype is given in
brackets. aIn tumours defined as mucinous the mucinous component was predominant.
malignancies not associated with virus and in sarcomas with-
out MDM2 amplification (Chang et al., 1993).
The mechanism underlying the formation of mucinous car-
cinoma in the presence of intact p53 is not known. The data
obtained on human colorectal carcinomas are supported by
observations made in vitro. Progression of the adenoma-
derived cell line PC/AA to the mucinous malignant
phenotype did not involve p53 protein overexpression, while
progression to the adenocarcinoma phenotype was associated
with the increase of cellular p53 protein expression (Williams
et al., 1993). Similarly, a spontaneous progression of a col-
onic adenoma cell line VACO-235 to mucinous carcinoma
occurred without mutations in the p53 gene (Markowitz et
al., 1994).
It is of particular interest that, similarly to colorectal
tumours, the mucinous carcinomas of the pancreas (Hoshi et
al., 1994; Zhang et al., 1994), breast (Domagala et al., 1993;
Marchetti et al., 1993) and ovary (Milner et al., 1993; Ren-
nison et al., 1994) show either no alterations in the p53 gene
nor in its expression, or the alterations are significantly less
frequent than in the non-mucinous tumours of the same
organs.
While the p53 gene, which is located on chromosome 17p,
appears to be less frequently mutated in mucinous tumours,
the less frequent loss of heterozygosity in mucinous than in
non-mucinous tumours was observed not only on
chromosome 17p (44% vs 88%) but also on chromosome 18q
(47% vs 85%) (Kern et al., 1989). Since the loss of
heterozygosity on chromosome 17p or 18q, however, is
generally less frequent in proximal than in the distal colon
(Thibodeau et al., 1993), the correlation of this property with
the mucinous phenotype must be verified on selected tumours
of either type from the proximal colon.
In tumours with non-mutated p53 the DNA index (which
is the ratio of DNA content of malignant cells to that of
normal cells) was reported to be lower than in those with
mutated p53 (Hamelin et al., 1994a), which would imply that
mucinous tumours may have a lower DNA index than non-
mucinous ones. Indeed, in mucinous tumours a higher
incidence of diploid pattern (Kanagawa et al., 1992) and a
lower DNA index than in the non-mucinous tumours (Lanza
et al., 1994) were observed, the latter apparently being
independent from tumour location (Lanza et al., 1994).
Highfrequency ofmutations in Ki-ras proto-oncogene
Ki-ras protein p21 belongs to the family of GTP/GDP bind-
ing proteins with GTPase activity, which participate in trans-
duction of mitogenic signals from the membrane to the cell
nucleus (Lowy and Willumsen, 1993). Mutated ras proteins
have a reduced GTPase activity and/or an increased dissocia-
tion rate of ras-GDP, leading to a prolonged mitogenic
signal (Egan and Weinberg, 1993).
Single-point mutations in the Ki-ras proto-oncogene
leading to substitution of critical amino acid residues in the
p21 protein are sufficient to confer transforming properties to
this gene (Reddy et al., 1982). In human colorectal car-
cinogenesis the alterations of the Ki-ras gene appear to occur
during the early steps of tumour formation, particularly dur-
ing the development of adenomatous polyps (Farr et al.,
1988; Vogelstein et al., 1988). The prevalence of Ki-ras muta-
tions increases in adenomas at a more advanced stage of
progression (Forrester et al., 1987; Fearon and Vogelstein,
1990) and reaches 50% in non-selected carcinomas (Fearon
and Vogelstein, 1990). In mucinous adenocarcinomas the
codons 12 and 13 are affected in 65% of cases, while in
non-mucinous ones the mutations occur in only 33% of these
loci (Laurent Puig et al., 1991). Of interest, in mucinous
ovarian tumours the prevalence of Ki-ras mutations is higher
than in the non-mucinous ones (Enomoto et al., 1991;
Ichikawa et al., 1994), indicating that also in ovarian
tumours the high frequency of Ki-ras mutation is preferen-
tially associated with the mucinous phenotype.
Amplification ofc-mycproto-oncogene
The c-myc-coded dimeric nuclear phosphoprotein binds to
DNA and regulates gene transcription; therefore it has
potential importance as a determinant of the proliferation
state of the cell (Kretzner et al., 1985; Dang, 1991; Marcu et
al., 1992). It has been proposed that abnormal myc expres-
sion would alter the regulation of cellular genes, rendering
cells more susceptible to malignant transformation. The
dominant action of another oncogene or the loss of a
tumour-suppressor gene would then accelerate or promote
tumorigenesis (Hunter, 1991). The myc gene co-operates with
ras to transform rat fibroblasts, rat embryo cells and human
epithelial cells (Marcu et al., 1992), but deregulated myc
expression alone is not sufficient to elicit malignant
phenotype in the absence of secondary events. Organ culture
experiments have shown further that activated ras and myc
genes together can induce malignant tumours without p53
mutation (Lu et al., 1992). The activation of the c-myc gene
may be of relevance for progression of colonic tumours since
the increase in-expression of c-myc mRNA and its protein
product correlates with dysplasia grade in adenomas and
with the progression from adenoma to colon carcinoma
(Erisman et al., 1985; Rothberg et al., 1985; Sikora et al.,
1987; Finley et al., 1989; Agnantis et al., 1991; Pavelic et al.,
1992; Tulchin et al., 1992; Hanski et al., 1994; Sato et al.,
1994).
The c-myc proto-oncogene is present as a single copy gene
in the normal human genome. In 54% of mucinous colorec-
tal carcinomas in a group of 13 American patients a modest
amplification of the c-myc gene was found, as compared with
7% (2/29) in moderately to well-differentiated non-mucinous
carcinomas (Heerdt et al., 1991). These authors associated
c-myc amplification with the more aggressive, malignantphenotype (Heerdt et al., 1991), a finding corroborated by
other workers (Kozma et al., 1994). In a study of 100 Asian
patients with colorectal cancer, however, no c-myc gene
amplification was detected (Smith et al., 1993). Further, the
tumours located distal to the transverse colon (the majority
of which are non-mucinous) overexpress c-myc more fre-
quently than the proximal tumours (Rothberg, 1987). The
slight increase in gene copy number detected in the American
patients (Heerdt et al., 1991) may have little effect on the
c-myc message expression, however, it indicates a different
frequency of proto-oncogene lesion in mucinous and non-
mucinous tumours in this group of patients.
Frequent overexpression ofmucin MUC2
MUC2 is a well-characterised intestinal mucin, present
predominantly in the small intestine and in the colon (Ho et
al., 1993). Strong expression is observed in 72% of the
mucinous but only in 21% of non-mucinous colonic car-
cinomas. Also 40-48% of colonic adenomas show strong
MUC2 expression. The comparison of expression in the
premalignant and malignant colonic tissues of the same spec-
imens indicated that MUC2 overexpression occurring in the
adenoma tissue is maintained or increased if the adenoma
progresses to mucinous carcinoma. If, however, the adenoma
develops into a non-mucinous adenocarcinoma, the expres-
sion frequently decreases below the normal level (Blank et
al., 1994). Thus the overexpression of MUC2 is occurring
already in the premalignant stage of the adenoma-carcinoma
sequence and remains a characteristic property of the
mucinous phenotype of colorectal tumours (Ho et al., 1993;
Blank et al., 1994).
The mechanisms responsible for MUC2 overexpression in
mucinous carcinomas is not known. The overexpression of
MUC2 in colon adenocarcinoma cells in vitro can be induced
by 12-O-tetradecanoyl phorbol acetate (TPA) or forskolin.
Both inducers have been shown to operate by triggering their
respective signal transduction pathways, via protein kinase
C-(TPA) or protein kinase A-(forskolin) (Velcich and Augen-
licht, 1993). Whether these transduction pathways are
involved in the MUC2 overexpression in vivo, has not been
investigated.
Morefrequent loss or low expression ofmajor
histocompatibility complex (MHC) class Imolecules
The products of the MHC play an important role in the
regulation of several immune functions: MHC class I
molecules serve as restriction elements for T-cell-mediated
cytotoxicity, whereas MHC class II molecules are required
for the presentation of antigens to autologous helper T cells,
MHC class I molecules are strongly expressed on mor-
phologically normal colonic epithelial cells and in colonic
adenomas (Van den Ingh et al., 1987; Garrido et al., 1993).
The investigation of 152 patients indicated that about 44%
of non-selected carcinomas exhibit a reduction or loss of
MHC class I molecules (Moller et al., 1991). The same study
indicated that the low expression or loss of MHC class I
antigens is more frequent in mucinous than in non-mucinous
tumours, a finding corroborating previous data from a
smaller group of patients (Van den Ingh et al., 1987).
The mechanism of MHC class I loss in carcinomas is not
known. Only two cumulative mutations in P2-microglobulin
(02-M) genes would be sufficient to induce complete loss of
MHC class I antigens. MHC class I-negative colon car-
cinomas lack also P2-M expression which was interpreted as
an indication that this may be the mechanism of MHC class
I loss in these tumours (Momburg and Koch, 1989; Cabrera
et al., 1991).
Lessfrequent loss ofMHC class IImolecules
Most normal epithelia, including colon, are MHC class II
negative (McDonald and Jewell, 1987). In colonic tissue the
majority of premalignant lesions acquire de novo MHC class
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II expression, and severely dysplastic colonic adenomas are
positive in 100% of cases. The progression to non-mucinous
adenocarcinoma is associated with a loss of expression of
MHC class II molecules in 68% of cases while in mucinous
carcinomas this loss is observed in only 37%. Thus the
mucinous carcinomas express MHC class II molecules about
twice as frequently as the non-mucinous ones (Garrido et al.,
1993).
Microsatellite instability
A subset of sporadic colorectal cancers and most of the
hereditary non-polyposis colorectal cancers (HNPCC) exhibit
widespread alterations of short, repeated sequences (micro-
satellites) distributed throughout the genome (Ionov et al.,
1993). The alteration of microsatellite length (or sequence)
that occurs during colon carcinogenesis is associated with
mutations in mismatch repair genes hMSH2, hMLH1,
hPMSI and hPMS2, which yield defective repair proteins
unable to correct replication errors (Bronner et al., 1994;
Loeb, 1994; Papadopoulos et al., 1994; Peltomaki, 1994;
Eshleman and Markowitz, 1995). Sporadic colorectal cancers
show replication errors in di- tri- or tetranucleotide loci in
13-16.5% of tumours (Aaltonen et al., 1993; Lothe et al.,
1993; Hamelin et al., 1994b; Kim et al., 1994). Among the
parameters that correlate with microsatellite instability in
these tumours is the proximal location, extracellular mucin
production and a trend towards less frequent p53 gene prod-
uct overexpression, as detected by immunohistochemistry
(Hamelin et al., 1994b; Kim et al., 1994). While among
non-mucinous tumours the frequency of replication error-
positive (RER+) phenotype was 9% (12/128), 66% of
mucinous tumors (6/9) were RER+ (Kim et al., 1994). There
is no relationship between p53 point mutations and mic-
rosatellite instability (Hamelin et al., 1994b). The question
whether the lesions in mismatch repair system substitute the
p53 mutations and represent an independent carcinogenesis
pathway associated with the mucinous phenotype warrants
further investigation. Further, the analysis of a large number
of tumours from both the distal and proximal colon is neces-
sary to establish how far the relative preponderance of
mucinous tumours in the proximal colon contributes to the
observed correlation.
Conclusions and aetiological implications
The recent genetic evidence in combination with the previous
data pose the question if the mucinous colorectal carcinoma
is a distinct genetic entity, different from the non-mucinous
carcinoma. Both types of colonic cancer differ not only in
their morphology but also in their localisation, incidence and
the pattern of genetic lesions. An intriguing observation is
that mucinous carcinomas not only of the colon but also of
other organs (breast, pancreas, ovary) appear to share certain
genetic properties. In these tumours the frequency of p53
mutations is lower and the frequency of Ki-ras mutations is
higher than in the corresponding non-mucinous tumours of
the same organs, suggesting a 'mucinous phenotype-related'
pathway of carcinogenesis. Since the definition of mucinous
tumours is based on quantitative rather than qualitative
criterion, this remains a hypothesis until the lesion(s) com-
mon to all mucinous carcinomas, responsible for the overexp-
ression of mucin genes and possibly related to the 'mucinous
pathway of carcinogenesis' are identified.
Different lesions may be due to a distinct aetiology of the
mucinous tumours. The role of the aberrantly expressed
mucin genes in this process is not clear since different
mucins, coded by genes localised on separate chromosomes,
predominate in different organs. One parameter emerging
from experimental studies as well as from retrospective
analysis of patient history is intestinal inflammation as a
factor facilitating the preferential development of the
mucinous phenotype in the colon. A comparative analysis ofGenotype and phenotype of mucinous cancer
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the genetic lesions of mucinous and non-mucinous tumours
would further our understanding of factors affecting
differentiation in colorectal cancer. Identification of the
genetic changes characteristic of the mucinous phenotype
may help not only to better understand its aetiology but
possibly establish markers for detection and surveillance of
the high-risk population.
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